CVS Health's analysis of Aetna insurance data shows that GLP-1 drugs, used for obesity and diabetes, could help employers and health plans break even if priced under $350 per month. These drugs reduce emergency room visits by 10%-12% and hospitalizations by up to 42% over three years, lowering medical costs. However, current prices paid by plans are too high to offset these savings, leading to increased overall spending. CVS hopes drugmakers will lower prices to improve affordability and reduce healthcare costs, especially as some companies drop coverage due to rising premiums.
CVS Health shares are trading at USD 89.35 as of Nov 16, 2026 01:01 WIB on Pluang, down slightly by 0.49% for the day. This price sits closer to the 52-week low of USD 70.08 than the high of USD 110.60, reflecting some market caution despite the company's analysis on GLP-1 drug pricing. CVS offers a dividend yield of 2.98%, with investors typically holding the stock for about 80 days on the platform.
